Nama's AI scorecard currently rates Kailera Therapeutics Sell (3.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does KLRA report earnings?

Kailera Therapeutics's next scheduled report is on Feb 10, 2027. Analysts expect EPS of -$1.16.

What is the KLRA price target?

The median analyst price target from 4 analysts is $42.00, with a range of $30.00 – $57.00.

Is KLRA Shariah compliant?

Nama's AAOIFI-style screen reads Kailera Therapeutics as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Kailera Therapeutics (KLRA)

Healthcare · Biotechnology · NASDAQ

Kailera Therapeutics (KLRA) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $1.68B and a free-cash-flow yield of -8.0%. Nama's AI scorecard rates it Sell, 3.2 out of 10.

AI scorecard

Sell · 3.2/10

Negative, at the mild end of Sell. As of Nov 7, 2026.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-54.1%

How far the last close sits under the highest price of the past five years.

Market cap	$1.68B
Trailing P/E	—
Price / book	1.5
Price / sales	—
FCF yield	-8.0%
Dividend yield	—
Gross margin	0.0%
Operating margin	0.0%
Net margin	0.0%
Revenue growth (YoY)	—
Revenue growth (3-yr annual)	—
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	—
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

KLRA earnings

Next report: Feb 10, 2027 (Q4 2026, EPS estimate -$1.16). Beat the EPS estimate in 1 of 3 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 4, 2026	-$0.74	-$1.01	+26.7%	$0
Q2 2026	Aug 12, 2026	-$1.09	-$0.73	-49.3%	$0
Q1 2026	May 26, 2026	-$3.65	-$0.55	-563.6%	$0

KLRA analyst price target

Median target $42.00 from 4 analysts, ranging $30.00 – $57.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live KLRA data on Nama Insights →

KLRA FAQ

Is KLRA a buy?: Nama's AI scorecard currently rates Kailera Therapeutics Sell (3.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does KLRA report earnings?: Kailera Therapeutics's next scheduled report is on Feb 10, 2027. Analysts expect EPS of -$1.16.
What is the KLRA price target?: The median analyst price target from 4 analysts is $42.00, with a range of $30.00 – $57.00.
Is KLRA Shariah compliant?: Nama's AAOIFI-style screen reads Kailera Therapeutics as Not Shariah Compliant. At least one of the three ratios or the industry test failed.